Childhood cancers trials in Spain

In Spain 152 Also abroad 2459

152 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Dabrafenib and/or Trametinib Rollover Study
Where
Barcelona, Madrid, Valencia
Age
18 years to 100 years
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Barcelona, Madrid, Oviedo
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 3Taking people
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Where
A Coruña, Barcelona, Córdoba, Girona, L'Hospitalet de Llobregat, Madrid, Valencia
Age
15 years and over
People
800 worldwide
Run by
AstraZeneca
See details and how to joinNCT06079671 · EU 2023-504374-38-00
Phase 2Taking people
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Where
Barcelona, Madrid
Age
1 year to 18 years
People
50 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07354074
Phase 2/3Taking people
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Where
Badalona, Madrid, Oviedo, Pozuelo de Alarcón, Salamanca, Valencia
Age
12 years and over
People
340 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07570173 · EU 2025-522267-15-00
Phase 2Taking people
A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)
Where
Barcelona, Esplugues de Llobregat, Madrid, Valencia
Age
12 years to 17 years
People
15 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07700758 · EU 2025-524515-37-00
Phase 4Taking people
Asciminib Roll-over Study
Where
Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Madrid, Santa Cruz de Tenerife, Santiago de Compostela, Sevilla, Valencia
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
Phase 2Taking people
177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
Where
Esplugues de Llobregat
Age
18 months to 64 years
People
24 worldwide
Run by
Jakob Stenman
See details and how to joinNCT04903899 · EU 2023-503684-42-00
Phase 1Taking people
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Where
Barcelona, Madrid, Pamplona
People
225 worldwide
Run by
Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
Phase 1/2Taking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
A Coruña, Barcelona, Madrid
Age
12 years and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00
Phase 1/2Taking people
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Where
Barcelona, Madrid
Age
6 months to 30 years
People
65 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05533775
Phase 3Taking people
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Where
Esplugues de Llobregat
Age
1 year to 64 years
People
130 worldwide
Run by
Memorial Sloan Kettering Cancer Center
See details and how to joinNCT07223021 · EU 2025-523096-34-00
Phase 1/2Taking people
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Where
Barcelona, Madrid
Age
Up to 17 years
People
37 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2023-504264-41-00 · EU 2023-504264-41-00
Phase 1/2Taking people
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Where
Barcelona, Madrid, Pamplona, Salamanca, Sevilla, Valencia
Age
2 years and over
People
420 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04811560 · EU 2023-506581-31-00
No phaseTaking people
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Where
Madrid
Age
10 years and over
People
210 worldwide
Run by
Leuko Labs, Inc.
See details and how to joinNCT06323447
Phase 2Taking people
Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS
Where
Barcelona, Madrid, Sevilla, Zaragoza, HOSPITAL CLINICO UNIVERSITARIO VIRGEN DE LA ARRIXACA
Age
15 years and over
People
20 worldwide
Run by
Italian Sarcoma Group
See details and how to joinNCT07328425 · EU 2024-519261-21-00
Phase 2/3Taking people
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Where
Badalona, Barcelona, Córdoba, Esplugues de Llobregat, Granada, Madrid, Málaga, Palma, Pamplona, Salamanca, Santander, Santiago de Compostela, Sevilla, Valencia
People
1,541 worldwide
Run by
Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00
No phaseNot yet taking people in Spain
Assessment of Intelligent Algorithms for Detection, Diagnosis and Risk Stratification of Tumors of the Kidney and Prostate
Where
Madrid
People
50 worldwide
Run by
Aristotle University Of Thessaloniki
See details and how to joinNCT07888322
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Barcelona, Esplugues De Llobregat, Madrid, Valencia
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 1/2Taking people
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Where
Barcelona, Esplugues de Llobregat, Madrid
Age
1 month to 17 years
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07630974 · EU 2025-522339-32-00
No phaseTaking people
Met Non Small Cell Cancer Registry (MOMENT)
Where
Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Seville, Valencia
People
700 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT05376891
Phase 1Taking people
Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors
Where
Barcelona, Logrono, Madrid, Pamplona, Valencia
Age
12 years and over
People
464 worldwide
Run by
Debiopharm International SA
See details and how to joinNCT04855656 · EU 2023-510063-35-00
Phase 1Taking people
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Where
Barcelona, Madrid
Age
24 months to 18 years
People
20 worldwide
Run by
ITM Solucin GmbH
See details and how to joinNCT06441331 · EU 2024-512831-66-00
No phaseTaking people
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Where
Valencia
Age
6 years and over
People
4,000 worldwide
Run by
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06459024
Phase 3Taking people
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Where
Alicante, Barakaldo, Barcelona, Esplugues de Llobregat, Madrid, Málaga, Murcia, Palma, Santiago de Compostela, Sevilla, Valencia, Zaragoza
Age
1 year to 64 years
People
750 worldwide
Run by
Charite University, Berlin, Germany
See details and how to joinNCT07476729 · EU 2023-509392-17-00